

Progress Report of the activities of the Working Group « Hypertension and the Kidney » 2016-2017

Contents

| | |
|---|---|
| Members | 2 |
| WG meetings and proceedings..... | 2 |
| Fibromuscular Dysplasia (FMD)..... | 4 |
| Hypertension in dialysis | 5 |
| Hypertension in renal transplantation | 6 |
| Publications on behalf of the WG | 6 |

Members

The updated list of members of the WG with their areas of interest is available on the ESH website:

<http://www.eshonline.org/esh-content/uploads/2015/02/WG-on-Hypertension-and-the-Kidney-2.pdf>

The WG is composed of 35 members from 15 countries.

The map shows the countries currently represented in the WG (except for Argentina and Japan).



The board is composed of: the Chair (Prof. Alexandre Persu, Belgium), the past Chair (Prof. Peter de Leeuw, The Netherlands), the Secretary (Dr Gregor Wuerzner, Switzerland) and an officer in charge of relations with ERA/EDTA (Prof. Patrick Rossignol, France). The statutes, approved in May 2016, are available on the website.

WG meetings and proceedings

The Chair and the Secretary have regular telephone conferences to organize and to follow progress of the objectives of the WG.

The next meeting of the Board is scheduled in Milan at the annual meeting of the ESH.

Newsletters are sent to the members on a regular basis to inform them about the activities and meetings proposed by the WG.

Scientific and business meetings

ESH 2017 Scientific meeting:

Friday, 16th June, 19:30-21:00; Yellow Hall 2

Chairpersons: A. Persu (Brussels, BELGIUM), G. Wuerzner (Lausanne, SWITZERLAND)

Program:

19.30-19.55: P. Sarafidis (Thessaloniki, GREECE)

European Consensus on Hypertension in Dialysis: focus on unmet research needs

20:00-20:25: A. Persu (Brussels, BELGIUM)

Fibromuscular dysplasia: recent advances and update on the European FMD initiative

20:30-20.55: M. Pruijm (Lausanne, SWITZERLAND)

Renal risk for hypertensive patients: Can BOLD MRI be useful?

ESH 2017 Business meeting:

Saturday, 17th June, 19:00-20:00, Yellow Hall 2

Chairs: A. Persu (Brussels, Belgium), G. Wuerzner (Lausanne, Switzerland)

Agenda:

- European Fibromuscular Dysplasia Initiative
- Consensus on HTN in dialysis
- Survey on BP measurement in dialysis
- Systematic review on HTN in renal transplantation
- New members; new projects
- Free proposals; varia

Fibromuscular Dysplasia (FMD)

The main objectives of the European FMD initiative are to (i) standardize clinical practice and update the European FMD consensus; (ii) establish a network of expert centres; (iii) establish a European patient association; (iv) establish a European registry; (v) dissect the genetics of FMD (GWAS/WES); (vi) coordinate research on FMD in Europe.

Meetings

The proceedings of the first Brussels FMD meeting, as well as the *rationale* and objectives of the European FMD initiative have been published as a brief review in *Hypertension* (2016;68(4):832-839).

The second Brussels FMD meeting, organized by the Chair of the WG and endorsed by the ESH, was held on 10th December 2016 in Brussels. It was in fact a truly European meeting with over 60 participants from 9 different countries. The Faculty included internationally recognized experts of FMD. A specific session was devoted to the role of patient associations.



Since the last report, the European FMD initiative has been presented in ten other meetings including between others: the Multidisciplinary Forum on Fibromuscular Dysplasia in Shanghai, China (22 September 2016), the annual Rhône-Alpes Nephrology/Hypertension meeting in Les Diablerets, Switzerland, - session organized by the Secretary (17 March 2017), the European Forum on Hypertension in Gdynia, Poland (11-13 May 2017), and the 2nd International Fibromuscular Dysplasia Research Network Symposium in Cleveland, USA (18-19 May 2017).

These presentations and contacts have led to the inclusion of new investigators and centres in the initiative, strengthening of collaborations with the US FMD registry, and development of an emerging European FMD patient network.

Registry

The registry, adapted from the French FMD registry coordinated by Prof P.-F. Plouin, includes over 50 items covering demographic and clinical characteristics of FMD, family history, type (uni- versus multifocal FMD), localization of FMD, associated features (aneurysm, dissection) and interventions (angioplasty, surgery...). A flexible, user-friendly online version has been developed (L. Toubiana), allowing to add an indefinite number of new events/visits. Specific modules can be developed according to local interests. The registry is linked to a wide-scale genetic project (Prof. X. Jeunemaitre, Paris).

As of now, 22 centres from 13 European countries have included over 400 patients in 19 months. Half of centres have begun to recruit during the last six months, and new centres will be ready to begin in the next weeks.

The registry collaborates with the ARCADIA (France) and ARCADIA-POL (Poland) networks, and has established links with centres from China, Argentina and Tunisia.

The WG is actively searching to recruit new centres, particularly in Northern and Central-Eastern Europe, which are currently less represented.

An official call for participation is available on the ESH website:

<http://www.eshonline.org/esh-content/uploads/2016/10/Call-FMD-registry-2016.pdf>


The support of the “Excellence centres” network to raise awareness about FMD and stimulate participation to the registry has been and remains of critical importance.

Hypertension in dialysis

The WG has initiated a strong collaboration with the European Renal and Cardiovascular Medicine (EURECA-m) WG of the ERA/EDTA (President: Prof. G. London, board member: Prof. P. Rossignol).

A consensus paper on the management of Hypertension in Dialysis has been jointly published in the *Journal of Hypertension and Nephrology, Dialysis and Transplantation* (see below).

An online survey on the adequacy of blood pressure measurements in dialysis centres across Europe has been completed in May 2017. Ninety-seven physicians working in dialysis centres from 36 countries have participated to the survey. Half of the centres originated from 7 countries (listed below). By end June 2017, a similar questionnaire for nurses and patients will be diffused by the WG, in order to confront the responses to those of physicians. The overall results should be available early in 2018.



Legend. Left: contribution of the 36 countries involved in the survey on blood pressure measurements in dialysis (% of centres). Right: list of 7 countries who jointly contributed for half of the centres.

Hypertension in renal transplantation

In the wake of the work performed on Hypertension in Dialysis, both working groups are currently initiating a systematic review on Hypertension in the Transplanted Patient.

Publications on behalf of the WG

Two reviews have been published on behalf of the WG:

- Persu A, Van der Niepen P, Touze E, *et al.* Revisiting Fibromuscular Dysplasia: Rationale of the European Fibromuscular Dysplasia Initiative. *Hypertension* 2016;68(4):832-839.
- Sarafidis PA, Persu A, Agarwal R, *et al.* Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). *J Hypertens* 2017;35(4):657-676 ; *Nephrol Dial Transplant*. 2017; 32(4):620-640.